Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1436

1.

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.

Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, Luan J, Ardanaz E, Arriola L, Balkau B, Boeing H, Deloukas P, Forouhi NG, Franks PW, Grioni S, Kaaks R, Key TJ, Navarro C, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Riboli E, Rolandsson O, Sacerdote C, Salamanca-Fernandez E, Slimani N, Spijkerman AM, Tjonneland A, Tumino R, van der A DL, van der Schouw YT, McCarthy MI, Barroso I, O'Rahilly S, Savage DB, Sattar N, Langenberg C, Scott RA, Wareham NJ.

JAMA. 2016 Oct 4;316(13):1383-1391. doi: 10.1001/jama.2016.14568.

PMID:
27701660
2.
3.

Lower and higher-potency statins on glycemic control in type 2 diabetes: A retrospective cohort study.

Bardini G, Giannini S, Rotella CM, Pala L, Cresci B, Mannucci E.

Diabetes Res Clin Pract. 2016 Oct;120:104-10. doi: 10.1016/j.diabres.2016.07.015.

PMID:
27525366
4.

Rosuvastatin decreases testosterone levels but not sexual function in men with type 2 diabetes.

Hsieh CJ, Huang B.

Diabetes Res Clin Pract. 2016 Oct;120:81-8. doi: 10.1016/j.diabres.2016.07.026.

PMID:
27525363
5.
6.

Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB.

Circulation. 2016 Jun 14;133(24):2459-502. doi: 10.1161/CIRCULATIONAHA.116.022194. Review.

PMID:
27297342
7.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
8.

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators..

J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.

PMID:
26988947
9.

Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.

Shimada A, Kimura H, Oida K, Kanehara H, Bando Y, Sakamoto S, Wakasugi T, Saga T, Ito Y, Kamiyama K, Mikami D, Iwano M, Hirano T, Yoshida H.

Lipids Health Dis. 2016 Mar 17;15:57. doi: 10.1186/s12944-016-0223-6.

10.
11.

Genetic insights into statin-associated diabetes risk.

Swerdlow DI, Preiss D.

Curr Opin Lipidol. 2016 Apr;27(2):125-30. doi: 10.1097/MOL.0000000000000272. Review.

PMID:
26959703
12.

Statin-Associated Diabetes Mellitus: Review and Clinical Guide.

Backes JM, Kostoff MD, Gibson CA, Ruisinger JF.

South Med J. 2016 Mar;109(3):167-73. doi: 10.14423/SMJ.0000000000000423. Review.

PMID:
26954655
13.

Capsule Commentary on Castro et al., Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Ching A.

J Gen Intern Med. 2016 May;31(5):535. doi: 10.1007/s11606-016-3638-x. No abstract available.

PMID:
26921159
14.

Statins and the risk of pancreatic cancer in Type 2 diabetic patients: Immortal time bias in survival analysis?

Hu YW.

Int J Cancer. 2016 Jul 1;139(1):232. doi: 10.1002/ijc.30064. No abstract available.

PMID:
26918933
15.

Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ 3rd, Caraballo PJ.

J Gen Intern Med. 2016 May;31(5):502-8. doi: 10.1007/s11606-015-3583-0.

PMID:
26850412
16.

Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.

Aslam M, Aggarwal S, Sharma KK, Galav V, Madhu SV.

PLoS One. 2016 Jan 25;11(1):e0145730. doi: 10.1371/journal.pone.0145730.

17.

Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.

Amigó N, Mallol R, Heras M, Martínez-Hervás S, Blanco Vaca F, Escolà-Gil JC, Plana N, Yanes Ó, Masana L, Correig X.

Sci Rep. 2016 Jan 18;6:19249. doi: 10.1038/srep19249.

18.

Treatment with atorvastatin attenuates progression of insulin resistance and pancreatic fibrosis in the Otsuka Long-Evans Tokushima fatty rats.

Wei L, Yamamoto M, Harada M, Otsuki M.

Metabolism. 2016 Feb;65(2):41-53. doi: 10.1016/j.metabol.2015.10.012.

PMID:
26773928
19.

EFFICACY OF 5 MG AND 10 MG ROSUVASTATIN IN TYPE-2 DIABETES MELLITUS WITH HYPERCHOLESTEROALEMIA.

Ullah F, Afridi AK, Rahim F, ur Rahman S, Ashfaq M.

J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):564-8.

PMID:
26721008
20.

The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study.

Tavaglione F, Filardi T, Fallarino M, Mandosi E, Turinese I, Rossetti M, Lenzi A, Morano S.

Nutr Metab Cardiovasc Dis. 2016 Feb;26(2):109-13. doi: 10.1016/j.numecd.2015.10.009.

PMID:
26712708
Items per page

Supplemental Content

Loading ...
Support Center